Nearly 8 years of follow-up & the triplet still delivers 💪

Gil Morgan, MD· @weoncologists · X·2026-10-23 22:35· 2 天前评分70

正文 · 原文

PEACE-1: adding abiraterone to ADT + docetaxel lifts 8-year OS from 27% to 40% in de novo mCSPC, regardless of metastatic volume.

The case for intensification just got stronger 👇
@RayMcDermott1 @BertrandTOMBAL #ESMO26 #ProstateCancer #OncoAlert4Sight

722 浏览 · 8 赞 · 4 转发 · 0 回复

会议摘要

2300TIPNCT07365995 NCT07365995 NCT07365995按 Metastatic prostate cancer 对上

BNT324-03: A phase 3, randomized, open-label trial comparing elfetabart drozuntecan, a B7H3 antibody-drug conjugate, with investigator's choice of docetaxel or cabazitaxel in patients with metastatic castration-resistant prostate cancer

https://esmocongress.esmo.org

LBA15按 Proffered paper 2: Breast cancer, early and advanced stage 对上

Anbenitamab plus albumin-bound docetaxel in patients (pts) with HER2-positive advanced breast cancer (BC): A randomized phase III study

https://esmocongress.esmo.org

NCT04884282NCT04884282按 - **标题 / Title：** Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED) 对上

- **标题 / Title：** Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)

https://esmocongress.esmo.org

来源：Gil Morgan, MD · x.com